A study evaluating pharmacokinetics, safety and tolerability of PBI-4050 in healthy volunteers and in patients with stable renal impairments.

Trial Profile

A study evaluating pharmacokinetics, safety and tolerability of PBI-4050 in healthy volunteers and in patients with stable renal impairments.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Cystic fibrosis; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Renal fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Sep 2017 New trial record
    • 01 Sep 2017 Results published in Clinical Pharmacology in Drug Development: 2017 Annual Meeting of the American College of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top